HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
touchEXPERT FOCUS for touchONCOLOGY
Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA.
The experts
Prof. Thomas Seufferlein, Ulm University, Ulm, Germany
Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Prof. Florian Lordick, University of Leipzig…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.